Australia's most trusted
source of pharma news
Posted 26 April 2024 PM
In what's likely to be the biggest comedown in CEO salaries reported this year, Biogen's Chris Viehbacher saw his remuneration package drop through the floor - by 87 per cent - but it had nothing to do with his performance.
The drop was expected given he received bumper financial incentives as part of a sign-on package when he took up the Biogen top job in November 2022. That year he was paid AU$45 million (US$30.6 million) for two months' work. But part of the deal meant Viehbacher didn't receive any stock or option awards for 2023.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.